Daclizumab Completed Phase 2 Trials for Age-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00304954Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration